Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Briacell Therapeutics Corp
Bullboard Posts
User Avatar Image
(77)
•••
Comment by ChupacabraBuenoon Jan 24, 2019 12:16pm
48 Views
Post# 29276060

RE:RE:New Poster Board from the Keystone Symposia Conference

RE:RE:New Poster Board from the Keystone Symposia Conference
Pandora wrote:
lakinisjuice1 wrote: https://briacell.com/wp-content/uploads/2019/01/Keystone-2019_BCTPoster_19yr0118.pdf


Keystone Symposium Conference
January 20 - 24, 2019
Fairmont Hotel Vancouver,
Vancouver, British Columbia, Canada

And today is January 23, 2019 -- maybe the presentation is drawing a little volume?



My theory is that the buy order for 2 millionish shares at $0-085 that was entered mid to late last week was done in anticipation of the Keysone Symposium Conference.

The timing was such that it could have been filled before the conference started, though it looks like it wasn't completely filled until yeterday. 

I think they placed a $170,000 bet that a reasonable analysis would suggest BCT to be undervalued and that any exposure was likely to bring in new buyers. Of course that's also they way I see it - so I hope they're right!

-GLTA

 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities